Presented in abstract form at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO); September 21-25, 2008; Boston, Massachusetts.
Applicability of randomized trials in radiation oncology to standard clinical practice
Article first published online: 14 MAY 2013
Copyright © 2013 American Cancer Society
Volume 119, Issue 16, pages 3092–3099, 15 August 2013
How to Cite
Apisarnthanarax, S., Swisher-McClure, S., Chiu, W. K., Kimple, R. J., Harris, S. L., Morris, D. E. and Tepper, J. E. (2013), Applicability of randomized trials in radiation oncology to standard clinical practice. Cancer, 119: 3092–3099. doi: 10.1002/cncr.28149
- Issue published online: 2 AUG 2013
- Article first published online: 14 MAY 2013
- Manuscript Accepted: 1 APR 2013
- Manuscript Revised: 14 MAR 2013
- Manuscript Received: 15 JAN 2013
- radiation oncology;
- randomized controlled trials;
- evidence-based medicine;
- health care policy;
- comparative effective research
Randomized controlled trials (RCTs) are commonly used to inform clinical practice; however, it is unclear how generalizable RCT data are to patients in routine clinical practice. The authors of this report assessed the availability and applicability of randomized evidence guiding medical decisions in a cohort of patients who were evaluated for consideration of definitive management in a radiation oncology clinic.
The medical records of consecutive, new patient consultations between January and March 2007 were reviewed. Patient medical decisions were classified as those with (Group 1) or without (Group 2) available, relevant level I evidence (phase 3 RCT) supporting recommended treatments. Group 1 medical decisions were further divided into 3 groups based on the extent of fulfilling eligibility criteria for each RCT: Group 1A included decisions that fulfilled all eligibility criteria; Group 1B, decisions that did not fulfill at least 1 minor eligibility criteria; or Group 1C, decisions that did not fulfill at least 1 major eligibility criteria. Patient and clinical characteristics were tested for correlations with the availability of evidence.
Of the 393 evaluable patients, malignancies of the breast (30%), head and neck (18%), and genitourinary system (14%) were the most common presenting primary disease sites. Forty-seven percent of all medical decisions (n = 451) were made without available (36%) or applicable (11%) randomized evidence to inform clinical decision making. Primary tumor diagnosis was significantly associated with the availability of evidence (P < .0001).
A significant proportion of medical decisions in an academic radiation oncology clinic were made without available or applicable level I evidence, underscoring the limitations of relying solely on RCTs for the development of evidence-based health care. Cancer 2013;119:3092—3099. © 2013 American Cancer Society.